Literature DB >> 1355756

Over-expression of P-glycoprotein and glutathione S-transferase pi in MCF-7 cells selected for vincristine resistance in vitro.

R D Whelan1, C J Waring, C R Wolf, J D Hayes, L K Hosking, B T Hill.   

Abstract

This study has provided evidence that exposure of the wild-type MCF-7 human breast carcinoma cell line to the mutagen ethyl methane sulphonate (EMS), followed by selection in vincristine (VCR), resulted in a stably-resistant subline, designated VCREMS, which expressed an approximately 14-fold level of resistance to VCR. This VCREMS subline showed cross-resistance (3-fold) to adriamycin (ADR) and to etoposide (3-fold), but not to cisplatin. The addition of a non-toxic concentration of verapamil (6.6 microM) significantly enhanced VCR cytotoxicity only in the resistant subline. This resistance was associated with over-expression of P-glycoprotein (Pgp), but without a concomitant increase in Pgp mRNA or gene amplification. In addition, activities of total glutathione S-transferases (GST) and glutathione peroxidase were elevated in this resistant subline, with over-expression of the GST-pi isozyme and its associated mRNA being identified, without gene amplification. This VCR-selected resistant MCF-7 cell line therefore provides another example of a breast carcinoma subline in which there is co-ordinate over-expression of both Pgp and GST-pi, without attributing a causal relationship to either event, and extends the range of anti-tumour drugs known to elicit modifications in glutathione metabolism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355756     DOI: 10.1002/ijc.2910520215

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines.

Authors:  Hélène Albert; Eric Battaglia; Carolino Monteiro; Denyse Bagrel
Journal:  Mol Oncol       Date:  2012-07-27       Impact factor: 6.603

2.  Transcriptional and post-transcriptional mechanisms can regulate cell-specific expression of the human Pi-class glutathione S-transferase gene.

Authors:  G J Moffat; A W McLaren; C R Wolf
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

3.  The effects of cyclosporin A, tamoxifen, and medroxyprogesterone acetate on the enhancement of adriamycin cytotoxicity in primary cultures of human breast epithelial cells.

Authors:  J A Claudio; J T Emerman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation.

Authors:  R D Whelan; B T Hill
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Glutathione S-transferase activity in patients with cancer of the digestive tract.

Authors:  G Severini
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 6.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 7.  Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.

Authors:  B T Hill
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 8.  Glutathione-related enzymes, glutathione and multidrug resistance.

Authors:  J A Moscow; K H Dixon
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

9.  Cell biological mechanisms of multidrug resistance in tumors.

Authors:  S M Simon; M Schindler
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

10.  In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.

Authors:  Susanna J E Veringa; Dennis Biesmans; Dannis G van Vuurden; Marc H A Jansen; Laurine E Wedekind; Ilona Horsman; Pieter Wesseling; William Peter Vandertop; David P Noske; GertJan J L Kaspers; Esther Hulleman
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.